Skyrizi (risankizumab) - AbbVie, Boehringer Ingelheim
Skyrizi: Regulatory submissions for Crohn's disease and psoriatic arthritis in 2021 (AbbVie) - Feb 8, 2020 - Pipeline Update 
Regulatory
https://investors.abbvie.com/static-files/0f2e0201-ef33-432c-904e-8cf78d2d0929
 
Feb 8, 2020
 
 
f5dadc7c-7102-40b2-830d-4d568f00300f.jpg